![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C28H38N6 |
Molar mass | 458.654 g·mol−1 |
3D model (JSmol) | |
| |
|
FGI-106 is a broad-spectrumantiviral drug developed as a potential treatment for enveloped RNA viruses, in particularviral hemorrhagic fevers from thebunyavirus,flavivirus andfilovirus families. It acts as an inhibitor which blocks viral entry into host cells. In animal tests FGI-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruseshantavirus,Rift Valley fever virus andCrimean-Congo hemorrhagic fever virus, the flavivirusdengue virus, and the filovirusesEbola virus andMarburg virus.[1][2][3][4][5]
![]() | Thisantiinfectivedrug article is astub. You can help Wikipedia byexpanding it. |